Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.63 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689961 | 1.00 | EGFR (0.63) | EGFRMAP4K1METCAMK2DALK | |
| SCHEMBL30689974 | 0.94 | MAP4K1 (0.61) | EGFRMAP4K1METALKIGF1R | |
| SCHEMBL26970238 | 0.94 | MAP4K1 (0.61) | EGFRMAP4K1METALKIGF1R | |
| SCHEMBL26970215 | 0.83 | EGFR (0.67) | EGFRMAP4K1METCAMK2DALK | |
| SCHEMBL29526468 | 0.83 | EGFR (0.67) | EGFRMAP4K1METCAMK2DALK | |
| SCHEMBL29525992 | 0.82 | EGFR (0.70) | EGFRMAP4K1ALKIGF1R | |
| SCHEMBL29526496 | 0.79 | MAP4K1 (0.73) | MAP4K1ALK | |
| SCHEMBL26970277 | 0.79 | MAP4K1 (0.73) | MAP4K1ALK | |
| SCHEMBL21846993 | 0.77 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL29526647 | 0.77 | MAP4K1 (0.65) | MAP4K1ALKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | PDXK, PHKG1, PHKG2 | EGFR 4265/4885MAP4K1 59/4885MET 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.